Skip to content
10-Q

Quarterly Report

CRISPR Therapeutics AG CRSP

0001193125-26-204188

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 96.45M sh
Shares Diluted Q1 2026 · Mar 31, 2026 96.05M sh
Shares Diluted Q1 2026 · Mar 31, 2025 85.94M sh
Capex Q1 2026 · Mar 31, 2026 $504K
Capex Q1 2026 · Mar 31, 2025 $206K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$108.9M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$53.95M
Long Term Debt Q1 2026 · Mar 31, 2026 $585.47M
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $423.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $347.56M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $235.18M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.81B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.92B
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.83B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.93B
Current Liabilities Q1 2026 · Mar 31, 2026 $136.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $149.12M
Total Liabilities Q1 2026 · Mar 31, 2026 $911.26M
Total Liabilities Q1 2026 · Dec 31, 2025 $343.43M
Current Assets Q1 2026 · Mar 31, 2026 $2.45B
Current Assets Q1 2026 · Dec 31, 2025 $1.99B
Total Assets Q1 2026 · Mar 31, 2026 $2.73B
Total Assets Q1 2026 · Dec 31, 2025 $2.27B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.58
Eps Basic Q1 2026 · Mar 31, 2026 −$1.28
Eps Basic Q1 2026 · Mar 31, 2025 −$1.58
Sga Expense Q1 2026 · Mar 31, 2026 $17.18M
Sga Expense Q1 2026 · Mar 31, 2025 $19.3M
Rd Expense Q1 2026 · Mar 31, 2026 $68.57M
Rd Expense Q1 2026 · Mar 31, 2025 $72.48M
Net Income Q1 2026 · Mar 31, 2026 −$122.93M
Net Income Q1 2026 · Mar 31, 2025 −$136M
Operating Income Q1 2026 · Mar 31, 2026 −$130.25M
Operating Income Q1 2026 · Mar 31, 2025 −$148.42M
Revenue Q1 2026 · Mar 31, 2026 $1.46M
Revenue Q1 2026 · Mar 31, 2025 $865K